Keystone Symposia on Drug Delivery to the Brain: Emerging Modalities

Breaking Barriers and Sharing Innovation with Leaders in Brain Drug Delivery

At Gate2Brain, we are committed to advancing the frontiers of drug delivery to the brain, and there’s no better place to discuss breakthroughs than the Keystone Symposia on Drug Delivery to the Brain: Emerging Modalities.

Our CEO, Meritxell Teixidó, had the incredible opportunity to engage with industry leaders and top scientists from Denali, Biogen, Roche, UCB, and other pharma giants, sharing insights and innovations in tackling one of the biggest challenges in drug development: crossing the blood-brain barrier.

A special highlight was reconnecting with Benjamí Oller, one of our former PhD students, who played a crucial role in discovering and developing MiniAp4, one of our pioneering peptide shuttles!

A New Era of Brain Drug Delivery

The Keystone Symposia emphasized the urgent need for better treatments for a wide range of devastating brain diseases, from neurodegenerative conditions to brain tumors and rare genetic disorders.

One of the biggest obstacles? Efficient and targeted drug delivery to the central nervous system (CNS).

At G2B, we address this challenge through our innovative peptide shuttle platform, designed to enhance the transport of a wide variety of therapeutics—including small molecules, peptides, nanoparticles, proteins, and antibodies—across biological barriers.

 Why It Matters

Our shuttle technology has the potential to transform drug delivery in multiple therapeutic areas, offering hope for patients who currently have limited or no treatment options.

We are thrilled to be part of this scientific revolution and to collaborate with key players in the field to push the boundaries of what’s possible in CNS drug delivery.